治験一覧
8,963 件中 3941〜3960 件を表示
中等度から重度のクローン病患者を対象とした、導入療法としてのオンタマリマブの有効性および安全性に関する研究（CARMEN CD 305）
The purpose of this study is to evaluate the efficacy and safety of ontamalimab in inducing clinical remission and endoscopic response in participants with moderate to severe Crohn's Disease.
症候性特発性または糖尿病性胃不全麻痺の成人患者におけるTAK-906の有効性および安全性を評価する研究
The purpose of this study is to assess the efficacy and safety of treatment with 2 dose levels of TAK-906 in adult participants with gastroparesis compared with placebo during 12 weeks of treatment.
ノルディトロピン®の長期使用に関する市販後調査（ヌーナン症候群による低身長）
The purpose of this study is to collect information about safety and effectiveness for long term use of Norditropin®. Participants will attend the medical institution according to usual practice and receive medical care, as agreed with the study doctor.
ボトックス®薬物使用調査（痙攣性発声障害）
This study is a drug use investigation program of BOTOX. The objective of this investigation is to collect and assess information on the safety and efficacy of BOTOX injections in subjects with a diagnosis of spasmodic dysphonia in daily clinical practice. All subjects treated with BOTOX for spasmodic dysphonia after obtaining approval for the indication of BOTOX for spasmodic dysphonia will be included in this study. Approximately 400 subjects will be included in the study. The observation period per subject will be up to 12 months from the date of the first administration of BOTOX. The total study duration will be will be approximately 3 years from the date of approval for the indication of BOTOX for spasmodic dysphonia. BOTOX is a registered trademark of Allergan, Inc.
特定のKRAS変異を有する固形腫瘍患者におけるソトラシブ（AMG 510）の安全性、忍容性、薬物動態、および有効性を評価する第1/2相試験（CodeBreaK 100）
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
小児患者におけるレバチオの長期使用に関する特別調査
Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice
本研究は、様々な種類の癌（固形腫瘍）患者におけるBI 905677の安全な投与量を特定し、試験することを目的としている。
This study is open to adults with different types of advanced cancer (solid tumours). This study is open to people in whom previous treatments were not successful. The purpose of this study is to find out the highest dose of BI 905677 the participants can tolerate. BI 905677 is a type of an antibody that is being developed to treat cancer. One dose of BI 905677 is given to the participants every 2 or 3 weeks as infusion into a vein. In this study, BI 905677 is given to humans for the first time. The participants visit the study site at least once a week so that the doctors can check their general health. The participants are in the study for as long as they benefit from and can tolerate treatment.
頭蓋内動脈瘤の治療におけるMICRUSFRAMEコイルとGALAXYコイルの性能を検証する研究
A post-market registry evaluating ruptured/unruptured aneurysms treated with MICRUSFRAME and GALAXY coils
手術可能なトリプルネガティブ乳がん患者における、アテゾリズマブ（抗PD-L1抗体）とアントラサイクリン／タキサン系補助化学療法の併用療法と化学療法単独療法を比較する研究
This study will evaluate the efficacy, safety, and pharmacokinetics of adjuvant atezolizumab in combination with paclitaxel, followed by atezolizumab, dose-dense doxorubicin or epirubicin (investigator's choice), and cyclophosphamide, compared with paclitaxel followed by dose-dense doxorubicin or epirubicin (investigator's choice) and cyclophosphamide alone in patients with Stage II-III TNBC (Triple Negative Breast Cancer)
Lynparza乳がん臨床経験調査
To characterise the development of ADRs of bone marrow depression in patients under actual post-marketing use
この研究では、BI 409306が統合失調症患者の症状悪化を予防するかどうかを検証します。この研究では、患者のBI 409306に対する忍容性と、6ヶ月間の投与期間における有効性について検証します。
The objective of the study is to investigate the efficacy, safety and tolerability of BI 409306 once daily compared with placebo given for 28 weeks in patients with schizophrenia on antipsychotic treatment. The study is designed to show superiority of BI 409306 over placebo in preventing relapse of schizophrenia symptoms.
ステンフィルコンAコンタクトレンズの臨床評価
This study is to evaluate the fitting performance of stenfilcon A contact lens (test) compared to narafilcon A contact lens (control).
進行性核上性麻痺（PSP）におけるABBV-8E12の延長試験
The purpose of this study was to assess the long-term safety and efficacy of ABBV-8E12 (tilavonemab) in participants with progressive supranuclear palsy (PSP).
プロテアソーム阻害剤ベースの注射療法で初期治療を受けた再発性および/または難治性多発性骨髄腫患者における、イキサゾミブとレナリドミドおよびデキサメタゾンの併用療法の有効性および安全性を評価する研究
The purpose of this study is to investigate the efficacy and safety of long-term administration of the oral proteasome inhibitor ixazomib as part of ixazomib in combination with lenalidomide and dexamethasone (IRd) therapy in patients with relapsed and/or refractory multiple myeloma (RRMM) treated initially with an injectable proteasome inhibitor-based therapy.
ループス腎炎患者におけるBI 655064の探索的維持療法試験
The main objectives of this trial are to evaluate the long term efficacy and safety of different doses of BI 655064 versus placebo as add-on therapy to Standard of Care (SOC) during maintenance therapy for lupus nephritis.
同種造血幹細胞移植（Allo-HSCT）を受ける患者における腸管急性移植片対宿主病（aGVHD）の予防におけるベドリズマブの使用
The purpose of this study is to evaluate the efficacy of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder.
急性リンパ性白血病の成人患者におけるポナチニブとイマチニブの比較試験
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib. The main aim of this study is to compare the number of participants on each treatment that show no signs of disease. Participants will take tablets of either ponatinib or imatinib at the same time each day combined with reduced-intensity chemotherapy for up to 20 months. Then, they will continue with single-agent therapy (ponatinib or imatinib) until they meet the discontinuation criteria from the study.
慢性腎臓病に伴う貧血を有するESA非服用透析患者を対象としたMT-6548の有効性および安全性評価試験（日本）
For hemodialysis subjects not receiving ESAs with anemia associated with chronic kidney disease, evaluate Hb correction and maintenance effect and safety of MT-6548.
うつ病を患う日本人小児および青年に対するデュロキセチン（LY248686）の治療効果に関する研究
The purpose of this long-term study is to evaluate the safety and efficacy of duloxetine hydrochloride in Japanese children and adolescents with depressive disorder.
重症下肢虚血患者におけるDES BTK血管ステントシステムとPTAの比較
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs. percutaneous transluminal angioplasty (PTA).